ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
1,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
1,3,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
2,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
3,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
3,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
3,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
3,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
4,1,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
4,2,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
4,3,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
5,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
5,2,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
6,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
7,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
8,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
8,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
9,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
9,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
10,1,Erythema induratum,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
11,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
11,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
12,1,Phlebitis,Phlebitis NEC,Vascular infections and inflammations,Vasc,N
13,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
13,2,Headache,Headaches NEC,Headaches,Nerv,N
13,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
13,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
13,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
14,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
15,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
15,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
15,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
16,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
17,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
18,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
18,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
19,1,Headache,Headaches NEC,Headaches,Nerv,N
19,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
20,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
20,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
21,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
21,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
21,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
22,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
22,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
22,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
23,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
24,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
25,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
25,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
26,1,Granuloma,Inflammations,General system disorders NEC,Genrl,N
26,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
27,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
27,2,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
27,3,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
28,1,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
28,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
29,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
29,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
29,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
29,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
30,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
31,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
32,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
32,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
33,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
33,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
34,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
34,2,Skin irritation,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
35,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
35,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
36,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
36,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
36,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
37,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
38,1,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
38,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
39,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
40,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
41,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
42,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
42,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
42,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
43,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
44,1,Visual field defect,Visual field disorders,Vision disorders,Eye,N
45,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
46,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
46,2,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
46,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
47,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
47,2,Headache,Headaches NEC,Headaches,Nerv,N
48,1,Hyperbilirubinaemia,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
48,2,Hypoglycaemia neonatal,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
49,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
50,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
51,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
52,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
53,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
54,1,Crystalluria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
55,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
55,2,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
56,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
56,2,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
57,1,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
58,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
59,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
60,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
60,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
60,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
61,1,Granulocytopenia,Neutropenias,White blood cell disorders,Blood,N
62,1,Hypocalcaemia,Calcium metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
63,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
64,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
64,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
64,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
65,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
65,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
66,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
67,1,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
68,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,Y
68,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
69,1,Retinitis,Eye and eyelid infections,Infections - pathogen unspecified,Infec,N
70,1,Night blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
70,2,Retinal pigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
71,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
72,1,Acute respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
72,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
73,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
73,2,Retinal pigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
74,1,Visual field defect,Visual field disorders,Vision disorders,Eye,N
74,2,Visual field defect,Visual field disorders,Vision disorders,Eye,N
75,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
76,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
76,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
77,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
77,2,Visual field defect,Visual field disorders,Vision disorders,Eye,N
78,1,Coma,Coma states,Neurological disorders NEC,Nerv,N
78,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
78,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
78,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
79,1,Visual field defect,Visual field disorders,Vision disorders,Eye,N
80,1,Blindness transient,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
81,1,Anaphylactoid reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
82,1,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
83,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
83,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
84,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
84,2,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
85,1,Bone development abnormal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
85,2,Growth retardation,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
86,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
87,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
88,1,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
88,2,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
88,3,Pyelonephritis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
89,1,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
89,2,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
90,1,Deafness,Hearing losses,Hearing disorders,Ear,N
91,1,Deafness,Hearing losses,Hearing disorders,Ear,N
91,2,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
92,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
93,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
94,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
95,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
95,2,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
95,3,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
95,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
95,5,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
95,6,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
95,7,Tongue oedema,Tongue signs and symptoms,Tongue conditions,Gastr,N
96,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
96,2,Headache,Headaches NEC,Headaches,Nerv,N
96,3,Myalgia,Muscle pains,Muscle disorders,Musc,N
96,4,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
96,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
96,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
97,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
97,2,Retinitis pigmentosa,Retinal disorders congenital,Eye disorders congenital,Cong,N
97,3,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
98,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
98,2,Delusion,Delusional symptoms,Disturbances in thinking and perception,Psych,N
99,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
99,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
100,1,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
100,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
100,3,Respiratory gas exchange disorder,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
101,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
102,1,Enteritis,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
102,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
103,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
103,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
103,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
104,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,Y
104,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
104,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
105,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
106,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
107,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
108,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
109,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
109,2,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
110,1,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
110,2,Fungal sepsis,Fungal infections NEC,Fungal infectious disorders,Infec,Y
110,3,Meningitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
110,4,Mucormycosis,Fungal infections NEC,Fungal infectious disorders,Infec,N
110,5,Myocardial necrosis,Myocardial disorders NEC,Myocardial disorders,Card,N
110,6,Pericarditis,Noninfectious pericarditis,Pericardial disorders,Card,N
110,7,Renal infarct,Renal vascular and ischaemic conditions,Renal disorders (excl nephropathies),Renal,N
110,8,Splenic infarction,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
111,1,Arrhythmia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
111,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
111,3,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
111,4,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
111,5,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
111,6,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
111,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
112,1,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
112,2,Optic neuropathy,Visual pathway disorders,Vision disorders,Eye,N
112,3,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
112,4,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
113,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
114,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
115,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
115,2,Optic neuritis,Optic nerve disorders NEC,Cranial nerve disorders (excl neoplasms),Nerv,N
116,1,Supraventricular tachycardia,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
117,1,Accidental overdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
117,2,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
118,1,Retinal pigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
119,1,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
120,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
121,1,Chronic kidney disease,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
122,1,Night blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
122,2,Retinal pigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
122,3,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
122,4,Visual field defect,Visual field disorders,Vision disorders,Eye,N
123,1,Muscle atrophy,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
124,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
124,2,Klebsiella sepsis,Klebsiella infections,Bacterial infectious disorders,Infec,Y
125,1,Klebsiella sepsis,Klebsiella infections,Bacterial infectious disorders,Infec,N
125,2,Laparoscopy,Gastrointestinal and abdominal imaging procedures,Gastrointestinal investigations,Inv,N
125,3,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
126,1,Cardiomyopathy,Cardiomyopathies,Myocardial disorders,Card,N
126,2,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
126,3,Splenectomy,Lymphoid tissue therapeutic procedures,Haematological and lymphoid tissue therapeutic procedures,Surg,N
126,4,Ventricular hypertrophy,Myocardial disorders NEC,Myocardial disorders,Card,N
126,5,Ventricular internal diameter abnormal,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
127,1,Ophthalmic herpes simplex,Herpes viral infections,Viral infectious disorders,Infec,N
128,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
128,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
128,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
129,1,Spinal fracture,Spinal fractures and dislocations,Bone and joint injuries,Inj&P,N
130,1,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
130,2,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
131,1,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
132,1,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
132,2,Magnetic resonance imaging abnormal,Imaging procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
133,1,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
133,2,Bone density decreased,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
133,3,High turnover osteopathy,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
133,4,Hypophosphataemia,Phosphorus metabolism disorders,"Bone, calcium, magnesium and phosphorus metabolism disorders",Metab,N
133,5,Osteopenia,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
133,6,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
133,7,Renal tubular disorder,Nephropathies and tubular disorders NEC,Nephropathies,Renal,N
133,8,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
133,9,Urine calcium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
134,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
134,2,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
135,1,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
135,2,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
135,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
136,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
136,2,Iron overload,Iron excess,Iron and trace metal metabolism disorders,Metab,N
136,3,Treatment noncompliance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
137,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
137,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
137,3,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
138,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
138,2,Macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
139,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
140,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
141,1,Extraocular muscle disorder,Ocular nerve and muscle disorders,Ocular neuromuscular disorders,Eye,N
142,1,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
143,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
143,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
143,3,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
143,4,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
143,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
143,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
143,7,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
144,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
144,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
145,1,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
145,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
145,3,Sickle cell anaemia,Haemoglobinopathies congenital,Blood and lymphatic system disorders congenital,Cong,N
146,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
146,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
147,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
147,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
147,3,Laryngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
147,4,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
147,5,Oedema mouth,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
148,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
148,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
149,1,Bone disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
149,2,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
149,3,Conductive deafness,Hearing losses,Hearing disorders,Ear,N
149,4,Ossicle disorder,Middle ear disorders NEC,Middle ear disorders (excl congenital),Ear,N
149,5,Tympanic membrane disorder,Tympanic membrane disorders (excl infections),Middle ear disorders (excl congenital),Ear,N
150,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
150,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
150,3,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
150,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
151,1,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
151,2,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
151,3,Phlebitis,Phlebitis NEC,Vascular infections and inflammations,Vasc,N
152,1,Cataract subcapsular,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
153,1,Exfoliative rash,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
153,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
154,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
154,2,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
154,3,Amylase increased,Digestive enzymes,Gastrointestinal investigations,Inv,N
154,4,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
154,5,Blood albumin decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
154,6,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
154,7,Blood creatinine decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
154,8,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
154,9,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
154,10,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,11,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,12,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
154,13,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
154,14,Lymphocyte count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,15,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,16,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
154,17,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
154,18,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
154,19,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
154,20,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
154,21,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
154,22,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
155,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
156,1,Deafness unilateral,Hearing losses,Hearing disorders,Ear,N
157,1,Anti-erythropoietin antibody positive,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
157,2,Aplasia pure red cell,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
157,3,Blood glucose abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
157,4,Fibula fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
157,5,Renal transplant,Renal therapeutic procedures,Renal and urinary tract therapeutic procedures,Surg,N
157,6,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
158,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
159,1,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
159,2,Osteoporotic fracture,Fractures NEC,Fractures,Musc,N
160,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
160,2,Colour vision tests abnormal,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
160,3,Conjunctival hyperaemia,"Conjunctival infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
160,4,Corneal oedema,"Corneal infections, oedemas and inflammations","Ocular infections, irritations and inflammations",Eye,N
160,5,Corneal striae,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
160,6,Deafness neurosensory,Hearing losses,Hearing disorders,Ear,N
160,7,Ocular toxicity,Ocular injuries NEC,Ocular injuries,Eye,N
160,8,Optic neuropathy,Visual pathway disorders,Vision disorders,Eye,N
160,9,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
160,10,Visual field defect,Visual field disorders,Vision disorders,Eye,N
161,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
161,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
161,3,Hepatic failure,Hepatic failure and associated disorders,Hepatic and hepatobiliary disorders,Hepat,N
162,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
162,2,Macular oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
162,3,Retinal pigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
162,4,Retinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
163,1,Azotaemia,Renal failure complications,Renal disorders (excl nephropathies),Renal,N
163,2,Blood urea increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
164,1,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
165,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
165,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
165,3,Abdominal tenderness,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
165,4,Blood bilirubin abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
165,5,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
165,6,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
165,7,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
165,8,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
165,9,Double heterozygous sickling disorders,Haemoglobinopathies congenital,Blood and lymphatic system disorders congenital,Cong,N
165,10,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
165,11,Foetal haemoglobin increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
165,12,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
165,13,Iron overload,Iron excess,Iron and trace metal metabolism disorders,Metab,N
165,14,Listless,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
165,15,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
165,16,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
165,17,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
165,18,Reticulocyte count abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
165,19,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
165,20,Sickle cell anaemia with crisis,Sickle cell trait and disorders,Haemoglobinopathies,Blood,N
165,21,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
165,22,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
166,1,Toxic epidermal necrolysis,Bullous conditions,Epidermal and dermal conditions,Skin,N
167,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
167,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
167,3,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
167,4,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
167,5,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
167,6,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
167,7,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
168,1,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
168,2,Retinal toxicity,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
168,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
169,1,Meningitis,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,Y
170,1,Blood copper decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
171,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
171,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
171,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
171,4,Pollakiuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
172,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
172,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
173,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
173,2,Dyspepsia,Dyspeptic signs and symptoms,Gastrointestinal signs and symptoms,Gastr,N
173,3,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
173,4,Proteinuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
173,5,Retinal dystrophy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
174,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
174,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
175,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
175,2,Retinal dystrophy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
176,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
176,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
177,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
177,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
178,1,Infusion site inflammation,Infusion site reactions,Administration site reactions,Genrl,N
178,2,Infusion site mass,Infusion site reactions,Administration site reactions,Genrl,N
178,3,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
179,1,Age-related macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
179,2,Corneal opacity,"Corneal structural change, deposit and degeneration","Anterior eye structural change, deposit and degeneration",Eye,N
179,3,Macular pigmentation,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
179,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
180,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
181,1,Gastric infection,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
181,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
181,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
181,4,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
182,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
183,1,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
183,2,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
184,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
185,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
185,2,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
185,3,Infusion site erythema,Infusion site reactions,Administration site reactions,Genrl,N
185,4,Infusion site warmth,Infusion site reactions,Administration site reactions,Genrl,N
185,5,Infusion site warmth,Infusion site reactions,Administration site reactions,Genrl,N
186,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
186,2,Extrasystoles,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
186,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
186,4,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
187,1,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
187,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
187,3,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
187,4,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
188,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
188,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
189,1,Device leakage,Device issues NEC,Device issues,Prod,N
189,2,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
189,3,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
189,4,Unintentional medical device removal,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
190,1,Deafness neurosensory,Hearing losses,Hearing disorders,Ear,N
191,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
191,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
191,3,Vascular device infection,Vascular infections,Infections - pathogen unspecified,Infec,N
192,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
193,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
193,2,Renal function test abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
193,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
193,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
194,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
194,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
195,1,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
195,2,Infusion site pruritus,Infusion site reactions,Administration site reactions,Genrl,N
195,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
195,4,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
196,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
196,2,Lower respiratory tract infection bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
196,3,Respiratory tract infection,Infections NEC,Infections - pathogen unspecified,Infec,N
197,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
197,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
198,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
199,1,Abscess,Infections NEC,Infections - pathogen unspecified,Infec,N
199,2,Cardiac iron overload,Cardiomyopathies,Myocardial disorders,Card,N
199,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
199,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
199,5,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
200,1,Agranulocytosis,Neutropenias,White blood cell disorders,Blood,N
200,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
200,3,Cardiac iron overload,Cardiomyopathies,Myocardial disorders,Card,N
200,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
201,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
201,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
201,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
202,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
202,2,Sickle cell anaemia with crisis,Sickle cell trait and disorders,Haemoglobinopathies,Blood,N
203,1,Foetal distress syndrome,Foetal complications NEC,Foetal complications,Preg,N
203,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
204,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
204,2,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
205,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
205,2,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
205,3,Subcutaneous abscess,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
206,1,Retinogram abnormal,Ophthalmic histopathology and imaging procedures,"Neurological, special senses and psychiatric investigations",Inv,N
206,2,Retinopathy sickle cell,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
207,1,Retinal haemorrhage,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
208,1,Blindness transient,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
209,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
209,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
209,3,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
209,4,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
210,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
210,2,Blood iron decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
210,3,Cardiac failure,Heart failures NEC,Heart failures,Card,N
210,4,Cyanosis,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
210,5,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
210,6,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
210,7,Glucose tolerance impaired,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
210,8,Glucose tolerance test abnormal,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
210,9,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
210,10,Hepatocellular carcinoma,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,N
210,11,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
210,12,Hypogonadism male,Male gonadal function disorders,Endocrine disorders of gonadal function,Endo,N
210,13,Insulin-like growth factor decreased,Endocrine analyses and imaging NEC,Endocrine investigations (incl sex hormones),Inv,N
210,14,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
210,15,Oedema,Oedema NEC,General system disorders NEC,Genrl,N
210,16,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
210,17,Thrombosis in device,Device malfunction events NEC,Device issues,Prod,N
210,18,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
211,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
211,2,Injection site haemorrhage,Injection site reactions,Administration site reactions,Genrl,N
212,1,Infusion site cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
213,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
213,2,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
214,1,Localised infection,Infections NEC,Infections - pathogen unspecified,Infec,N
215,1,Deafness,Hearing losses,Hearing disorders,Ear,N
215,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
216,1,Laryngeal disorder,Laryngeal and adjacent sites disorders NEC (excl infections and neoplasms),Upper respiratory tract disorders (excl infections),Resp,N
216,2,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
217,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
218,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
219,1,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
220,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
220,2,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
220,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
220,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
221,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
222,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
223,1,Central serous chorioretinopathy,Retinopathies NEC,"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
223,2,Colour blindness,Ocular disorders congenital NEC,Eye disorders congenital,Cong,N
223,3,Metamorphopsia,Visual disorders NEC,Vision disorders,Eye,N
223,4,Serous retinal detachment,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
223,5,Subretinal fluid,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
223,6,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
224,1,Haematological infection,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
225,1,Incorrect drug administration rate,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
225,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
226,1,Body temperature abnormal,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
226,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
226,3,Musculoskeletal discomfort,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
227,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
228,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
229,1,Administration site mass,Administration site reactions NEC,Administration site reactions,Genrl,N
229,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
230,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
231,1,Headache,Headaches NEC,Headaches,Nerv,N
231,2,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
231,3,Incorrect drug administration rate,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
231,4,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
232,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
233,1,Obstruction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
234,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
235,1,Eye swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
235,2,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
235,3,Maculopathy,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
235,4,Retinal disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
235,5,Retinal oedema,"Retinal, choroid and vitreous infections and inflammations","Ocular infections, irritations and inflammations",Eye,N
235,6,Visual field defect,Visual field disorders,Vision disorders,Eye,N
235,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
235,8,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
236,1,Deafness neurosensory,Hearing losses,Hearing disorders,Ear,N
237,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
238,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
239,1,Vision blurred,Visual disorders NEC,Vision disorders,Eye,N
240,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
240,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
240,3,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
240,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
241,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
241,2,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
241,3,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
242,1,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
243,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
244,1,Cataract,Cataract conditions,"Anterior eye structural change, deposit and degeneration",Eye,N
245,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
246,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
246,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
246,3,Fanconi syndrome,Renal disorders congenital,Renal and urinary tract disorders congenital,Cong,N
246,4,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
246,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
246,6,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
247,1,Expired product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
248,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
249,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
250,1,Disease recurrence,General signs and symptoms NEC,General system disorders NEC,Genrl,N
250,2,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
250,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
250,4,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
250,5,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
251,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
251,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
252,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
253,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
254,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
255,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
256,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
257,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
258,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
259,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
259,2,Spinal disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
260,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
260,2,Spinal disorder,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
261,1,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
261,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
262,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
262,2,Spinal X-ray abnormal,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
263,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
263,2,Spinal X-ray abnormal,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
264,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
265,1,Retinogram abnormal,Ophthalmic histopathology and imaging procedures,"Neurological, special senses and psychiatric investigations",Inv,N
265,2,Spinal X-ray abnormal,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
266,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
267,1,Ototoxicity,Ear disorders NEC,Aural disorders NEC,Ear,N
268,1,Bone development abnormal,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
268,2,Growth retardation,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
268,3,Spinal X-ray abnormal,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
269,1,Spinal X-ray abnormal,Musculoskeletal and soft tissue imaging procedures,Musculoskeletal and soft tissue investigations (excl enzyme tests),Inv,N
270,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
270,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
271,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
271,2,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
272,1,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
273,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
274,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
275,1,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
276,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
277,1,Organ failure,General signs and symptoms NEC,General system disorders NEC,Genrl,N
278,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
279,1,Blood iron abnormal,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
279,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
280,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
280,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
280,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
280,4,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
281,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
282,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
283,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
284,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
284,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
284,3,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
285,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
285,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
285,3,Helicobacter infection,Helicobacter infections,Bacterial infectious disorders,Infec,N
286,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
286,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
287,1,Mass,Mass conditions NEC,Tissue disorders NEC,Genrl,N
287,2,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
287,3,Wound secretion,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
288,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
289,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
289,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
290,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
291,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
292,1,Macular dystrophy congenital,Retinal disorders congenital,Eye disorders congenital,Cong,N
292,2,Retinal vein occlusion,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
293,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
293,2,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
293,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
293,4,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
294,1,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
295,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
296,1,Injection site paraesthesia,Injection site reactions,Administration site reactions,Genrl,N
296,2,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
297,1,Injection site paraesthesia,Injection site reactions,Administration site reactions,Genrl,N
298,1,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
299,1,Infusion site reaction,Infusion site reactions,Administration site reactions,Genrl,N
300,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
301,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
302,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
302,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
303,1,Hypoacusis,Hearing losses,Hearing disorders,Ear,N
304,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
305,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
306,1,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
307,1,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
308,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
309,1,Headache,Headaches NEC,Headaches,Nerv,N
309,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
309,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
309,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
310,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
310,2,Device defective,Device physical property and chemical issues,Device issues,Prod,N
310,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
310,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
311,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
311,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
311,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
312,1,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
313,1,Serum sickness,Allergic conditions NEC,Allergic conditions,Immun,N
314,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
314,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
315,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
316,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
317,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
318,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
